A detailed history of Two Sigma Investments, LP transactions in Zai Lab LTD stock. As of the latest transaction made, Two Sigma Investments, LP holds 65,888 shares of ZLAB stock, worth $1.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
65,888
Holding current value
$1.56 Million
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$13.72 - $21.55 $903,983 - $1.42 Million
65,888 New
65,888 $1.14 Million
Q1 2023

May 15, 2023

BUY
$30.21 - $48.1 $516,591 - $822,510
17,100 New
17,100 $568,000
Q2 2022

Aug 15, 2022

SELL
$23.14 - $49.68 $967,622 - $2.08 Million
-41,816 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$27.77 - $64.4 $10.2 Million - $23.6 Million
-367,206 Reduced 89.78%
41,816 $1.84 Million
Q4 2021

Feb 14, 2022

BUY
$54.9 - $105.21 $11.9 Million - $22.7 Million
216,132 Added 112.05%
409,022 $25.7 Million
Q3 2021

Nov 15, 2021

BUY
$105.0 - $178.37 $19.6 Million - $33.4 Million
187,074 Added 3216.54%
192,890 $20.3 Million
Q2 2021

Aug 16, 2021

SELL
$125.11 - $180.0 $14.4 Million - $20.7 Million
-115,080 Reduced 95.19%
5,816 $1.03 Million
Q1 2021

May 17, 2021

BUY
$126.27 - $191.71 $14.7 Million - $22.4 Million
116,780 Added 2837.22%
120,896 $16.1 Million
Q4 2020

Feb 16, 2021

SELL
$81.94 - $135.34 $565,386 - $933,846
-6,900 Reduced 62.64%
4,116 $557,000
Q3 2020

Nov 16, 2020

SELL
$73.3 - $89.48 $263,880 - $322,128
-3,600 Reduced 24.63%
11,016 $916,000
Q2 2020

Aug 14, 2020

BUY
$48.82 - $82.53 $453,342 - $766,373
9,286 Added 174.22%
14,616 $1.2 Million
Q1 2020

May 15, 2020

SELL
$39.1 - $62.9 $499,932 - $804,239
-12,786 Reduced 70.58%
5,330 $274,000
Q4 2019

Feb 14, 2020

BUY
$29.79 - $43.06 $539,675 - $780,074
18,116 New
18,116 $753,000

Others Institutions Holding ZLAB

About Zai Lab Ltd


  • Ticker ZLAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,908,704
  • Market Cap $2.31B
  • Description
  • Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...
More about ZLAB
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.